Literature DB >> 29110151

Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.

Leah K Lambert1, Lynda G Balneaves2, A Fuchsia Howard3, Carolyn C Gotay4.   

Abstract

BACKGROUND: Adjuvant endocrine therapy (AET) significantly reduces recurrence and mortality in women with breast cancer (BrCa). Despite the efficacy of AET in improving BrCa outcomes, up to 50% of women do not adhere to prescribed AET regimens. While numerous demographic and clinical predictors influence adherence and persistence, few studies have identified the patient-reported factors that influence AET adherence and persistence.
PURPOSE: The aim was to examine the patient-reported personal, social, and structural factors influencing BrCa survivors' adherence and persistence with AET.
METHODS: An integrative review was undertaken wherein PubMed, Medline, CINAHL, Embase, and PsycINFO databases were searched using keyword descriptors and database subject headings. Inclusion criteria included quantitative or qualitative peer-reviewed studies written in English that assessed AET adherence and/or persistence through objective measurement or self-report and included patient-reported factors found to influence adherence and/or persistence. The data extracted from eligible studies were entered into a matrix, and systematically compared and iteratively analyzed using relational autonomy as an organizing theoretical framework.
RESULTS: A total of 43 manuscripts (9 qualitative and 34 quantitative) were reviewed. Several personal, social, and structural factors were identified that influenced AET adherence and persistence, including side effects, necessity beliefs, self-efficacy, the patient-healthcare provider relationship, social support, and continuity of follow-up care.
CONCLUSIONS: An increasing number of studies have focused on identifying the patient-reported factors that influence AET adherence and persistence. This review highlights important personal, social, and structural factors that act as facilitators and barriers in adhering to and persisting with long-term AET. Acknowledging and addressing these factors is key to providing women with the care needed to improve suboptimal adherence and persistence.

Entities:  

Keywords:  Adjuvant endocrine therapy; Breast cancer; Cancer survivorship; Integrative review; Medication adherence; Medication persistence; Patient-reported outcomes

Mesh:

Substances:

Year:  2017        PMID: 29110151     DOI: 10.1007/s10549-017-4561-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  34 in total

1.  It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

2. 

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

3.  A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.

Authors:  Jamie M Jacobs; Kathryn Post; Katina Massad; Nora K Horick; Emily A Walsh; Julia Cohn; Chelsea S Rapoport; Amy J Clara; Michael H Antoni; Steven A Safren; Ann H Partridge; Jeffrey M Peppercorn; Elyse R Park; Jennifer S Temel; Joseph A Greer
Journal:  Cancer       Date:  2022-08-04       Impact factor: 6.921

4.  Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.

Authors:  Miryam Yusufov; Margo Nathan; Aleta Wiley; Julia Russell; Ann Partridge; Hadine Joffe
Journal:  Breast Cancer Res Treat       Date:  2020-09-12       Impact factor: 4.872

5.  Impact of patients' refusal to undergo adjuvant treatment measures on survival.

Authors:  H Männle; J W Siebers; F Momm; K Münstedt
Journal:  Breast Cancer Res Treat       Date:  2020-09-24       Impact factor: 4.872

6.  Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen L K Chia; Carolyn C Gotay
Journal:  Curr Oncol       Date:  2021-04-09       Impact factor: 3.677

7.  Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Authors:  Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach
Journal:  Breast Cancer Res Treat       Date:  2022-03-11       Impact factor: 4.872

8.  Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study.

Authors:  Zerko Wako; Daniel Mengistu; Negalign Getahun Dinegde; Tseganesh Asefa; Mulugeta Wassie
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-06-09

9.  Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.

Authors:  Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

10.  THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care.

Authors:  Janeane N Anderson; Rebecca A Krukowski; Andrew J Paladino; J Carolyn Graff; Lee Schwartzberg; Andrea N Curry; Gregory A Vidal; Tameka N Jones; Teresa M Waters; Ilana Graetz
Journal:  J Hosp Manag Health Policy       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.